Advertisement
Screener

BIOGEN INC. (BIIB) Gain (Loss) on Investments

2.1 / 5 stars · 50/118 Roast Me

BIOGEN INC. Gain (Loss) on Investments

BIOGEN INC. (BIIB) reported Gain (Loss) on Investments of $15.06 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-03.

Discontinued › Income Statement › Other Income

us-gaap:GainLossOnInvestments · last filed 2012-02-03

  • BIOGEN INC. gain (loss) on investments for the quarter ending 2011-12-31 was -$318.00K, a 252.88% decline year-over-year.
  • BIOGEN INC. gain (loss) on investments for the quarter ending 2011-09-30 was -$159.00K, a 103.30% decline year-over-year.
  • BIOGEN INC. gain (loss) on investments for the quarter ending 2011-06-30 was -$358.00K, a 105.67% decline year-over-year.
  • BIOGEN INC. gain (loss) on investments for the quarter ending 2011-03-31 was $15.90M, a 218.90% increase year-over-year.
  • BIOGEN INC. gain (loss) on investments for fiscal 2011 was $15.06M, a 7.71% decline from fiscal 2010.
  • BIOGEN INC. gain (loss) on investments for fiscal 2010 was $16.32M, a 31.92% decline from fiscal 2009.
  • BIOGEN INC. gain (loss) on investments for fiscal 2009 was $23.97M.
  • BIOGEN INC. gain (loss) on investments for fiscal 2008 was -$1.08M.
Period endGain (Loss) on Investments 3 monthGain (Loss) on Investments 3 month as first filedGain (Loss) on Investments 6 monthGain (Loss) on Investments 6 month as first filedGain (Loss) on Investments 9 monthGain (Loss) on Investments 9 month as first filedGain (Loss) on Investments 12 monthGain (Loss) on Investments 12 month as first filed
2011-12-31-$318.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03
-$477.00K
derived: sum of 2 quarters · filed 2012-02-03
-$835.00K
derived: sum of 3 quarters · filed 2012-02-03
$15.06M
10-K · filed 2012-02-03
2011-09-30-$159.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28
-$517.00K
derived: sum of 2 quarters · filed 2011-10-28
$15.38M
10-Q · filed 2011-10-28
$15.59M
derived: sum of 4 quarters · filed 2012-02-03
2011-06-30-$358.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26
$15.54M
10-Q · filed 2011-07-26
$15.75M
derived: sum of 3 quarters · filed 2012-02-03
$20.56M
derived: sum of 4 quarters · filed 2012-02-03
2011-03-31$15.90M
10-Q · filed 2011-04-21
$16.11M
derived: sum of 2 quarters · filed 2012-02-03
$20.92M
derived: sum of 3 quarters · filed 2012-02-03
$27.23M
derived: sum of 4 quarters · filed 2012-02-03
2010-12-31$208.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03
$5.02M
derived: sum of 2 quarters · filed 2012-02-03
$11.34M
derived: sum of 3 quarters · filed 2012-02-03
$16.32M
10-K · filed 2012-02-03
2010-09-30$4.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28
$11.13M
derived: sum of 2 quarters · filed 2011-10-28
$16.11M
10-Q · filed 2011-10-28
$22.90M
derived: sum of 4 quarters · filed 2012-02-03
2010-06-30$6.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26
$11.30M
10-Q · filed 2011-07-26
$18.09M
derived: sum of 3 quarters · filed 2012-02-03
$19.84M
derived: sum of 4 quarters · filed 2012-02-03
2010-03-31$4.99M
10-Q · filed 2011-04-21
-$4.99M
10-Q · filed 2010-04-20
$11.77M
derived: sum of 2 quarters · filed 2012-02-03
$13.53M
derived: sum of 3 quarters · filed 2012-02-03
$33.27M
derived: sum of 4 quarters · filed 2012-02-03
2009-12-31$6.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03
$8.54M
derived: sum of 2 quarters · filed 2012-02-03
$28.29M
derived: sum of 3 quarters · filed 2012-02-03
$23.97M
10-K · filed 2012-02-03
-$23.97M
10-K · filed 2010-02-09
2009-09-30$1.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26
$21.50M
derived: sum of 2 quarters · filed 2010-10-26
$17.18M
10-Q · filed 2010-10-26
-$17.18M
10-Q · filed 2009-10-21
$12.33M
derived: sum of 4 quarters · filed 2011-02-04
2009-06-30$19.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20
$15.43M
10-Q · filed 2010-07-20
-$15.43M
10-Q · filed 2009-07-17
$10.58M
derived: sum of 3 quarters · filed 2011-02-04
$20.28M
derived: sum of 4 quarters · filed 2011-02-04
2009-03-31-$4.31M
10-Q · filed 2010-04-20
-$9.16M
derived: sum of 2 quarters · filed 2011-02-04
$537.00K
derived: sum of 3 quarters · filed 2011-02-04
2008-12-31-$4.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04
$4.85M
derived: sum of 2 quarters · filed 2011-02-04
-$1.08M
10-K · filed 2011-02-04
$1.08M
10-K · filed 2010-02-09
2008-09-30$9.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21
$3.77M
10-Q · filed 2009-10-21
2008-06-30-$5.93M
10-Q · filed 2009-07-17
2007-12-31-$16.73M
10-K · filed 2010-02-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29